Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.02 -0.45 (-0.90%)
Streaming Delayed Price Updated: 1:34 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo
Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk. 
Via Investor's Business Daily
Topics Economy Lawsuit
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle
Pfizer sues Metsera and Novo Nordisk, alleging breach of contract and antitrust violations over a rival $9 billion bid challenging its $4.9 billion merger deal. 
Via Benzinga
Topics Lawsuit
The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit
Via Stocktwits
2 Beaten-Down Stocks That Could Be About to Rally
It would be best to get in before the rest of the market pounces on these opportunities. 
Via The Motley Fool
Novo Nordisk A/S (NYSE:NVO): A Top Dividend Stock with Strong Profitability and Financial Health
Novo Nordisk (NVO) is a top dividend stock with a 3.6% yield, strong growth, and a sustainable payout backed by exceptional profitability and financial health. 
Via Chartmill
Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera
Via Stocktwits
Novo Nordisk Submits Revised Bid For Metsera, Enters A Bidding War With Pfizer
Via Stocktwits
P/E Ratio Insights for Novo Nordisk
 
Via Benzinga
Should You Buy Viking Therapeutics Before Nov. 5?
Viking's stock surged in one trading session after a positive clinical trial report last year. 
Via The Motley Fool
Is It Time to Dump Your Shares of Pfizer?
Pfizer stock has dropped 50% over the past three years. 
Via The Motley Fool
Topics Intellectual Property
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal
Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller company. 
Via Investor's Business Daily
Topics Law Enforcement Lawsuit
Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise
Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism. 
Via Stocktwits
Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain
As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush. 
Via Benzinga
Topics ETFs
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera. 
Via Investor's Business Daily
Topics Economy Government
Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'
Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action. 
Via Benzinga
1 Incredible Reason to Buy Novo Nordisk Stock (NVO) in November -- or Sooner
It offers compelling weight-loss drugs -- and a compelling stock price, too. 
Via The Motley Fool
Novo Nordisk Shares Fell 5.6% After President Trump Commented on Future Price Cuts for Weight Loss Drugs. Should Investors Be Worried?
It's not the end of the world for the drugmaker. 
Via The Motley Fool
Topics Government Intellectual Property
If I Could Only Buy 2 Stocks in the Last Quarter of 2025, I'd Pick These
These two have been neglected by Wall Street too much. 
Via The Motley Fool
Healthcare Sector Navigates Volatile Waters as S&P 500 Closes: A Deep Dive into Key Market Drivers
As the closing bell rings on October 27, 2025, the S&P 500 Healthcare sector stands at a critical juncture, exhibiting the nuanced volatility that defines this essential yet complex segment of the... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
What Is 1 of the Best Pharmaceutical Stocks to Buy Now?
This pharma giant is entering the rapidly expanding market for weight loss drugs. 
Via The Motley Fool
Viking Therapeutics: High Risk, High Reward Play
Via MarketBeat
Options Corner: A Reliable Quant Signal Just Flashed Again For Pharma Giant Novo Nordisk
While Novo Nordisk has been victimized by broader market pressure, NVO stock has just flashed a reliable quant signal for bullish traders. 
Via Benzinga
Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership
 
Via Benzinga
Topics Initial Public Offering
Breakout Momentum Plays You Need to Know About
Three stocks may draw the attention of momentum investors—QURE spiked in September, OMER in October, and SDST has almost 1,000% in upside potential. 
Via MarketBeat
Weight Loss Drugs Are Quietly Exploding Employer Health Insurance Costs: 'There Is A Quiet Alarm Bell Going Off'
Employer-sponsored health insurance costs rise for third year, with average family premiums at $27,000 in 2025. Drug costs and GLP-1s drive spending. 
Via Benzinga
Marjorie Taylor Greene Buys 6 Stocks And Bitcoin ETF: Here's Her Latest Shopping List
Congresswoman Marjorie Taylor Greene (R-Ga.) is among the most active traders in Congress. Here's a look at her latest trades disclosed, which comes with increased attention on Congress Trades from... 
Via Benzinga
Novo Nordisk Shares Tumble Amid Sweeping Board Overhaul
Copenhagen, Denmark – October 22, 2025 – Novo Nordisk (NYSE: NVO) shares experienced a notable decline this week following the announcement of a comprehensive board overhaul, a decisive move... 
Via MarketMinute
Topics Economy Government Intellectual Property
3 Things Investors Need to Know Ahead of Eli Lilly's Q3 Earnings Report
The rapid growth rates of recent years aren't guaranteed to continue. 
Via The Motley Fool
Topics Intellectual Property
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.